• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

The Framingham Heart Study: Research to Clinical Practice Timeline

Slideshow

Slideshow

Findings from the Framingham Heart Study since its 1948 beginning have led to identification of and treatment for dozens of risk factors for cardiovascular disease. Which ones?

Framingham Heart Study

Framingham Heart Study

The Framingham Heart Study (FHS) was launched in 1948 with a federal grant of just $500 000 with the purpose of identifying common factors or characteristics that contribute to cardiovascular disease (CVD). In the early 1900s, heart disease was the leading cause of death and treatment was rendered only after a serious event--and was not always successful.

It was an original FHS investigator who introduced the concept of "risk factors" for CVD and the idea that with treatment their impact on CV health could be mitigated. Risk factors identified based on FHS data include elevated LDL, smoking, hypertension, diabetes. Positive influences identified include the benefits of exercise and the protective properties of HDL cholesterol.

FHS is multigenerational and multiracial/multiethnic. In the slides that follow, we provide an at-a-glance look at the first 50 years of breakthroughs.


Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2024 MJH Life Sciences

All rights reserved.